Abstracts tagged "SLE"

Abstract Number: 662 • 2019 ACR/ARP Annual Meeting
Utility of a Mobile Phone Based Application to Collect Patient-Reported Outcome Information from People Living with Systemic Lupus Erythematosus
Brooke Williams¹, Bridget Muckian ¹, Claire Dykas ², Christine Peschken ³, Richard Furie ⁴, Elena Massarotti ⁵, Vanja sikirica ⁶, Steven Gilbert ⁷, Martin Hodge ⁷ and Peter Lipsky ⁸, ¹AMPEL BioSolutions, Charlottesville, VA, ²AmpelBioSolutions, Charlottesville, VA, ³University of Manitoba, Winnepeg, Canada, ⁴Northwell Health, Great Neck, NY, ⁵Brigham and Women's Hospital/Harvard Medical School, Boston, MA, ⁶Pfizer, Boston, MA, ⁷Pfizer, Boston, ⁸AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Patient Reported Outcomes (PROs) can provide important data about the impact of a disease on an individual and/or the quality of the response to…
Abstract Number: 942 • 2019 ACR/ARP Annual Meeting
A Randomized Prospective Trial to Assess the Clinical Utility of Multianalyte Assay with Complement Activation Products in Diagnosing Systemic Lupus Erythematosus
Daniel Wallace¹, Roberta Alexander ², Tyler O'Malley ³, Arezou Khosroshahi ⁴, Mehrnaz Hojjati ⁵, Konstantinos Loupasakis ⁶, Jeffrey Alper ⁷, Yvonne Sherrer ⁷, Maria Fondal ⁷, Rajesh Kataria ⁸, Tami Powell ², Claudia Ibarra ², Sonali Narain ⁹, Elena Massarotti ¹⁰, Arthur Weinstein ² and Thierry Dervieux ², ¹Cedars Sinai Medical Center/UCLA, Los Angeles, CA, ²Exagen, Vista, CA, ³Exagen, Oceanside, CA, ⁴Emory University, Atlanta, GA, ⁵Department of Rheumatology, Loma Linda University, Loma Linda, CA, ⁶MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ⁷BendCare Rheumatology, Naples, FL, ⁸Southern Ohio Rheumatology, Wheelersburg, OH, ⁹Northwell Health, Great Neck, Long Island, NY, ¹⁰Brigham and Women's Hospital/Harvard Medical School, Boston, MA
Background/Purpose: Cell-Bound Complement Activation Products (CB-CAPs) in multianalyte assay panel (MAP) is a diagnostic immunology laboratory test with established clinical validity in distinguishing systemic lupus…
Abstract Number: 1574 • 2019 ACR/ARP Annual Meeting
Causes of Death in SLE: Analysis of Inpatient Death from 2000-2018 in a Tertiary Care Hospital in India
Sarit Sekhar Pattanaik¹, Hafis Muhammed ², Amita Aggarwal ³, Able Lawrence ⁴, Vikas Agarwal ², Durga P Misra ², Latika Gupta ⁴ and Ramnath Misra ⁴, ¹Sanjay Gandhi post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, ²SGPGI, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India
Background/Purpose: Mortality in Systemic lupus erythematosus (SLE) has reduced over the years but it is still two to three folds as compared to general population.…
Abstract Number: 1864 • 2019 ACR/ARP Annual Meeting
Gaps in Care for Patients with SLE: Data from the ACR’s RISE Registry
Gabriela Schmajuk¹, Zara Izadi ², Michael Evans ³ and Jinoos Yazdany ⁴, ¹UCSF, SFVAMC Division of Rheumatology, San Francisco, CA, ²UCSF Division of Rheumatology, San Francisco, ³University of California San Francisco, San Francisco, ⁴UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: Although multiple national quality measures focus on the management and safety of rheumatoid arthritis, few measures address the care of patients with SLE. We…
Abstract Number: 2555 • 2019 ACR/ARP Annual Meeting
Antimalarial-Induced Cardiomyopathy: Outcome in 10 Patients
Konstantinos Tselios¹, Dafna Gladman ², Shadi Akhtari ³, Paula Harvey ³, Kate Hanneman ⁴ and Murray Urowitz ⁵, ¹University Health Network, University of Toronto, Toronto, Canada, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³Women's College Hospital, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Antimalarial-induced cardiomyopathy (AMIC) is a hypertrophic cardiomyopathy with conduction system disorders, cardiac biomarker abnormalities and a short-term mortality of 45%. Data on the reversibility…
Abstract Number: 667 • 2019 ACR/ARP Annual Meeting
The PROMIS-29 as a Measure of Type 1 and 2 SLE Activity
Nathaniel Harris¹, Amanda Eudy ², Megan Clowse ², Lisa Criscione-Schreiber ², Jayanth Doss ², Rebecca Sadun ², Jennifer Rogers ² and Kai Sun ², ¹Duke University Medical Center, Durham, NC, ²Duke University, Durham
Background/Purpose: We have developed a new conceptual model that characterizes lupus into subtypes based on physician- and patient-reported measures: Type 1 is assessed by the…
Abstract Number: 975 • 2019 ACR/ARP Annual Meeting
Functional Impairment of Mitf and the MiT Transcription Factor Family Dysregulates B Cell Activation and Function
Abhimanyu Amarnani¹, Ramile Dilshat ², Nikita Malakhov ³, Brian Ghezelaiagh ⁴, Chongmin Huan ¹, Erna Magnusdottir ², Eirikur Steingrimsson ² and Christopher Roman ¹, ¹SUNY Downstate Medical Center, Brooklyn, ²University of Iceland Biomedical Center, Reykjavik, Iceland, ³SUNY Downstate Medical Center, New York Presbyterian-Weill Cornell Medical Center, Brooklyn, ⁴SUNY Downstate Medical Center, Stony Brook University, Brooklyn
Background/Purpose: Autoreactive B cells are central in the development of many autoimmune diseases, such as systemic lupus erythematosus (SLE), and are normally eliminated or inactivated…
Abstract Number: 1575 • 2019 ACR/ARP Annual Meeting
Lymphocyturia Is a Good and Cheap Biomarker for Active Lupus Nephritis and Is Sensitive to Change
Sarit Sekhar Pattanaik¹, Ankita Singh ², Shilpa Venkataraman ³, Ramnath Misra ⁴, Vinita Agrawal ² and Amita Aggarwal ⁵, ¹Sanjay Gandhi post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Post Graduate institute of medical science, Lucknow, India, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India, ⁵Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Multiple urinary biomarkers have been described for lupus nephritis, however none has reached the clinic due to either complex methodology or low discriminatory power.…
Abstract Number: 1941 • 2019 ACR/ARP Annual Meeting
Interactions Between Genome-Wide Genetic Factors and Current Smoking in Determining SLE Risk
Jing Cui¹, Soumya Raychaudhuri ², Cameron Speyer ², Susan Malspeis ², Hongshu Guan ³, Xinyi Liu ², Jessica Williams ², Emma Davenport ⁴, Rachel Knevel ⁵, Elizabeth Karlson ² and Karen Costenbader ², ¹Brigham Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, ⁴Sanger Institute, Cambridge, United Kingdom, ⁵Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: We have previously reported that current smoking (or having recently quit within 4 years) was associated with elevated risk of SLE, in particular anti-dsDNA+…
Abstract Number: 2577 • 2019 ACR/ARP Annual Meeting
SLE Disease Activity May Be Associated with Choroidal Thickness
Iris Lee¹, Brigid Marshall ¹, Prabha Ranganathan ², Seth Eisen ³, Rithwick Rajagopal ¹, Alfred Kim ³ and Tingting Li ¹, ¹Washington University in St Louis, St Louis, ²Washington University in St Louis, St Louis, MO, ³Washington University School of Medicine, Saint Louis, MO
Background/Purpose: SLE is an autoimmune disease with widespread organ involvement. High disease activity has previously been associated with higher risk of organ damage and mortality.…
Abstract Number: 668 • 2019 ACR/ARP Annual Meeting
Lack of Uptake of Prophylactic Human Papilloma Virus (HPV) Vaccination Among Women with Systemic Lupus Erythematosus (SLE) in the Detroit, MI Area, a High Risk Population
J. Patricia Dhar¹, Louis Saravolatz ² and Susan Szpunar ³, ¹Wayne State University, Bloomfield Hills, MI, ²Ascension St. John Hospital and Wayne State University, Grosse Pointe Woods, MI, ³Ascension St. John Hospital Hospital, Grosse Pointe Woods, MI
Background/Purpose: Women with SLE are at increased risk for cervical neoplasia likely because of infection with high risk (HR) HPV and thus should be considered…
Abstract Number: 1016 • 2019 ACR/ARP Annual Meeting
Identification of Differentially Expressed Genes and Signaling Pathways in Systemic Lupus Erythematosus by Integrated Bioinformatics Analysis
Wei Liu¹, Yuanhao Wu ¹ and Wenjia Zhao ¹, ¹First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a common autoimmune disease. The occurrence and development of SLE is a result of multiple factors, but its exact…
Abstract Number: 1576 • 2019 ACR/ARP Annual Meeting
Prevalence and Outcome of Thrombocytopenia in Systemic Lupus Erythematosus – Single Centre Cohort Analysis
Tatiana Costa Pires¹, Raquel Caparrós-Ruiz ² and David A Isenberg ³, ¹Serviço de Medicina 1, Centro Hospitalar de Leiria, Leiria, Portugal, ²UGC de Reumatologia, Instituto de Investigación Biomédica de Málaga, Hospital Universitario de Málaga, Universidad de Málaga, Málaga, Spain, ³Centre for Rheumatology, London, United Kingdom
Background/Purpose: To characterize the frequency of thrombocytopenia in SLE and determine its time of onset during the course of the disease, severity and impact on mortality.Methods: This…
Abstract Number: 2022 • 2019 ACR/ARP Annual Meeting
Analysis of Gene Expression from Systemic Lupus Erythematosus Synovium Reveals Unique Pathogenic Mechanisms
Erika Hubbard¹, Michelle Catalina ², Sarah Heuer ¹, Prathyusha Bachali ², Nicholas Geraci ³, Peter Lipsky ³ and Amrie Grammer ¹, ¹AMPEL BioSolutions and RILITE Research Institute, Charlottesville, VA, ²AMPEL BioSolutions and the RILITE Research Institute, Charlottesville, VA, ³AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Arthritis is a common manifestation of SLE and the ability of a new lupus therapy often depends on its ability to suppress joint inflammation.…
Abstract Number: 2784 • 2019 ACR/ARP Annual Meeting
Alterations in Inflammatory, TNF-Superfamily, and IFN-Associated Chemokines Precede Clinical Changes in SLEDAI After Methylprednisolone Treatment of SLE Patients
Melissa E. Munroe¹, Carla J. Guthridge ¹, Sarah Kleckner ¹, Ly Tran ², Joel Guthridge ³, Debra J. Zack ⁴, Judith James ³ and Joan T. Merrill ⁵, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Xencor, Inc., San Diego, CA, ⁵Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: SLE is typified by a wide spectrum of clinical manifestations and immune dysregulation. Corticosteroids are almost universally effective, but marked by unacceptable side effects.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].